Activities Report & Appendix 4C
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
30 July 2015
ACTIVITY REPORT & APPENDIX 4C
Melbourne, Australia; 30 July 2015: Regenerative medicine company Cynata Limited’s Quarterly Cash Flow
Report for the quarter ended 30 June 2015 is attached.
CAPITAL STRATEGY and PARTNERING: As in the prior quarter, Cynata engaged in an active investor outreach
program to better inform the investor community of the Company’s activities. This resulted in growing interest
and demand that culminated on 15 July in the Company placing approximately 6.67 million fully-paid ordinary
shares to several major US institutional investors with significant interests in the biotech investment sector.
The placement also included one attaching 13-month option for every 2 ordinary shares issued and one
attaching 5-year option for every 2 ordinary shares issued. The Company chose to take advantage of this
unique opportunity to both broaden the shareholder register and to strengthen the Company’s balance sheet.
In addition to bringing in sophisticated US investors along with the collateral benefits of raising the Company’s
US profile, it also provides a more solid foundation for partnering activities and facilitates investigation of the
highly promising field of cell-based cancer therapy.
Management has witnessed very positive corporate events in the sector and for Cynata in particular, with two
recent transactions involving companies in the stem cell space: one being a US$205m license agreement and
collaboration between Athersys, Inc. and Chugai Pharmaceutical Co., Ltd (majority owned by pharma industry
giant Roche) and the other being the ~US$307m acquisition of Cellular Dynamics International, Inc. ("CDI") by
Fujifilm Holdings Corporation. These deals confirm the growing interest in stem cell assets by leaders in the
pharmaceutical industry and underscores Cynata’s own deal-making strategy. Notably, the CDI transaction is
relevant to Cynata given the business relationship between Cynata and CDI, announced on 18 September
2014. This relationship provides Cynata with licensing rights to certain intellectual property and to a clinical
grade human induced pluripotent stem cell (iPSC) line manufactured by CDI and now held at Cynata’s contract
manufacturer, Waisman Biomanufacturing. CDI’s business activities are focussed predominantly on the
development and sale of human cell products for use as research tools in a variety of applications and the
acquisition demonstrates Fujifilm’s enthusiasm for top quality regenerative medicine assets.
PRODUCT DEVELOPMENT: During the quarter the Company completed a number of important milestones in
the development of its proprietary platform Cymerus™ therapeutic mesenchymal stem cell (MSC) technology:
GMP-Grade Manufacture: a range of testing procedures have shown that Cymerus MSCs produced at the
Company’s US-based contract manufacturer Waisman Biomanufacturing consistently meet expectations and
attain standards appropriate for their intended clinical use. This provides a high level of confidence that
Cynata’s proprietary manufacturing process is robust and reproducible: absolute requirements for the
manufacture of a therapeutic product.
Master Cell Bank: Cynata has developed an effectively limitless starting material for production of the
Company’s first therapeutic, off-the-shelf MSC product, CYP-001, with the manufacture, testing and release of
a clinical-grade iPSC Master Cell Bank (MCB).
Clinical Trial Centres: Cynata has progressed arrangements with several leading hospitals of international
standing to conduct the planned Phase 1 clinical study in graft-versus-host disease (GvHD).
Interaction with Regulatory Agencies: The Company has continued discussions with regulatory authorities in
relation to the proposed Phase 1 clinical study. Satisfactory completion of these discussions will facilitate a
decision on the location and finalising a schedule for commencement and completion of the trial.
CONTACTS:
Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com
Kirin Smith, Chief Operations Officer, Investor Contact, + 1 646-863-6519, ksmith@pcgadvisory.com
Sean Leous, Chief Communications Officer, Media Contact, +1 646-863-8998, sleous@pcgadvisory.com
Cynata Therapeutics Limited – Suite 1, 1233 High Street, Armadale, Victoria 3143 - PO Box 7165, Hawthorn North, Victoria 3122
T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com
W: www.cynata.com ABN - 98 104 037 372 \
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a
therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader
in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of
production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at
commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a
mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor
limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical
business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell
therapeutics and provides both a unique differentiator and an important competitive position.
Cynata Therapeutics Limited – Suite 1, 1233 High Street, Armadale, Victoria 3143 - PO Box 7165, Hawthorn North, Victoria 3122
T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com
W: www.cynata.com ABN - 98 104 037 372
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Rule 4.7B
Appendix 4C
Quarterly report
for entities admitted
on the basis of commitments
Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10
Name of entity
Cynata Therapeutics Limited
ABN
Quarter ended (“current quarter”)
98 104 037 372
30 June 2015
Consolidated statement of cash flows
Current quarter
Year to date
(12 months)
$A’000
Cash flows related to operating activities
$A’000
1.1
Receipts from customers
1.2
Payments for:
(a) staff costs
(b) advertising and marketing
(c) research and development
(d) leased assets
(e) other working capital
Dividends received
Interest and other items of a similar nature
received
Interest and other costs of finance paid
Income taxes paid
1.3
1.4
1.5
1.6
1.7
-
-
(91)
(94)
(847)
(195)
-
(381)
(224)
(2,198)
(556)
-
21
-
89
-
Other (provide details if materials)
- TRIP rebate received /insurance
recoveries
- R&D rebate received
282
4
282
Net operating cash flows
(924)
(2,984)
+ See chapter 19 for defined terms.
17/12/2010
Appendix 4C Page 3
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Current quarter
Year to date
(12 months)
$A’000
$A’000
1.8
(924)
(2,984)
-
-
-
-
Loans to other entities
Loans repaid by other entities
Other (provide details if material)
-
-
Net investing cash flows
-
-
Total operating and investing cash flows
(924)
(2,984)
Cash flows related to financing activities
Proceeds from issues of shares, options,
etc.
Proceeds from sale of forfeited shares
Proceeds from borrowings
Repayment of borrowings
Dividends paid
Other (provide details if material)
-
2,179
-
Net financing cash flows
-
2,179
Net increase (decrease) in cash held
(924)
(805)
1.21
1.22
Cash at beginning of quarter/year to date
Exchange rate adjustments to item 1.21
5,479
116
5,095
381
1.23
Cash at end of quarter
4,671
4,671
1.9
1.10
1.11
1.12
1.13
1.14
1.15
1.16
1.17
1.18
1.19
1.20
Net operating cash flows (carried forward)
Cash flows related to investing activities
Payment for acquisition of:
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current assets
(e) other non-current assets
Proceeds from disposal of:
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current assets
(e) other non-current assets
+ See chapter 19 for defined terms.
Appendix 4C Page 4
17/12/2010
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities
Current quarter
$A'000
1.24
Aggregate amount of payments to the parties included in item 1.2
207
1.25
Aggregate amount of loans to the parties included in item 1.11
-
1.26
Explanation necessary for an understanding of the transactions
Directors’ fees, salaries including superannuation benefits and professional
consultancy fees. All payments are on normal commercial terms.
Non-cash financing and investing activities
2.1
Details of financing and investing transactions which have had a material effect on
consolidated assets and liabilities but did not involve cash flows
N/A
2.2
Details of outlays made by other entities to establish or increase their share in businesses in
which the reporting entity has an interest
N/A
Financing facilities available
Add notes as necessary for an understanding of the position.
3.1
Loan facilities
3.2
Credit standby arrangements
Amount available
$A’000
N/A
Amount used
$A’000
N/A
N/A
N/A
+ See chapter 19 for defined terms.
17/12/2010
Appendix 4C Page 5
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Reconciliation of cash
Reconciliation of cash at the end of the quarter
(as shown in the consolidated statement of cash
flows) to the related items in the accounts is as
follows.
4.1
Cash on hand and at bank
4.2
Current quarter
$A’000
Previous quarter
$A’000
-
2
Deposits at call
4,671
5,477
4.3
Bank overdraft
-
-
4.4
Other (provide details)
-
-
4,671
5,479
Total: cash at end of quarter (item 1.23)
Acquisitions and disposals of business entities
5.1
Name of entity
5.2
5.4
Place of
incorporation or
registration
Consideration for
acquisition or
disposal
Total net assets
5.5
Nature of business
5.3
Acquisitions
(Item 1.9(a))
Disposals
(Item 1.10(a))
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
+ See chapter 19 for defined terms.
Appendix 4C Page 6
17/12/2010
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Compliance statement
1
This statement has been prepared under accounting policies which comply with accounting
standards as defined in the Corporations Act (except to the extent that information is not
required because of note 2) or other standards acceptable to ASX.
2
This statement does give a true and fair view of the matters disclosed.
Sign here:
_________________________________
Print name:
Dr Ross Macdonald
(Managing Director)
Date: 28 July 2015
Notes
1.
The quarterly report provides a basis for informing the market how the entity’s activities have
been financed for the past quarter and the effect on its cash position. An entity wanting to
disclose additional information is encouraged to do so, in a note or notes attached to this
report.
2.
The definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report
except for any additional disclosure requirements requested by AASB 107 that are not
already itemised in this report.
3.
Accounting Standards. ASX will accept, for example, the use of International Financial
Reporting Standards for foreign entities. If the standards used do not address a topic, the
Australian standard on that topic (if any) must be complied with.
+ See chapter 19 for defined terms.
17/12/2010
Appendix 4C Page 7
Share your feedback
Discover